News   Jun 25, 2019
 49     0 
News   Jun 24, 2019
 405     0 
News   Jun 24, 2019
 1.1K     2 

Sanofi Pasteur Expansion (1755 Steeles Av W, 3s, WBA/IPS)

interchange42

Administrator
Staff member
Member Bio
Joined
Apr 23, 2007
Messages
21,952
Reaction score
16,030
Location
by the Humber
This is the former U of T Connaught Laboratories site to the east of Dufferin. Now Sanofi Pasteur, a pharmaceuticals and vaccines manufacturer, there are about 30 buildings spread across the 54-acre site which borders the West Don River. Far to the south end of the site (hidden from Steeles), they've applied to build a new 15,000 square metre, 2-storey (plus the mechanical floor) vaccine manufacturing facility. The building is proposed to straddle a Ravine and Natural Feature Protection zone, and the whole site is on Toronto's Inventory of Heritage Properties… so there are some complications.

In any case, the Heritage Impact Assessment is an interesting read for a site with a lot of history. Check it out at this link.

42
 

AlvinofDiaspar

Moderator
Member Bio
Joined
Apr 22, 2007
Messages
25,588
Reaction score
12,273
Location
Toronto
While it is unrealistic to expect Frank Gehry to come up with an industrial building, it would be nice to see some attempt at good architecture - e.g. Novartis campus in NY and Basel.

AoD
 

interchange42

Administrator
Staff member
Member Bio
Joined
Apr 23, 2007
Messages
21,952
Reaction score
16,030
Location
by the Humber
Here's the press release that came from that ceremony:

SANOFI TO INVEST €350 MILLION IN CANADIAN VACCINE FACILITY
Apr 12, 2018

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)

  • Expansion demonstrates company's commitment to innovation and leadership in global public health
  • New Toronto facility is one of the largest-ever investments by Sanofi in a single building
  • Significantly increases capacity to meet growing demand for pediatric and booster vaccines
TORONTO, April 12, 2018 /CNW Telbec/ - Sanofi is investing €350 million (CAD $500 million) for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. The investment bolsters the company's Canadian operations and its commitment to advancing public health around the world.

The announcement will be made during an event today at Sanofi Pasteur's Toronto facility. Attendees will include the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development, Government of Canada, the Honourable Steven Del Duca, Minister of Economic Development and Growth, Government of Ontario, and members of Sanofi's executive leadership.

"Canada has a strong legacy in the research and development of vaccines. With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe," said David Loew, Executive Vice President and Head of Sanofi Pasteur. "Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease."

The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand of five-component acellular pertussis (5-acP) antigen. Upon completion in 2021, the new building will also be equipped to produce the antigens used in the diphtheria and tetanus vaccines.

"This project is one of the most important investments for the Sanofi global industrial network," said Philippe Luscan, Executive Vice President, Global Industrial Affairs, Sanofi. "It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world."

About the Sanofi Pasteur Canadian Facilities

Founded as the Connaught Antitoxin Laboratories and University Farm in 1917, Sanofi Pasteur's Canadian facility has supported numerous scientific breakthroughs while making significant public health contributions. The Toronto site was home to the world's first large-scale commercial insulin production and was the sole supplier of the diabetes treatment to Canadians until the 1980s. It also produced a highly accessible antitoxin for diphtheria, the leading public health threat to Canadian children in the early 1900s, and was an important partner in the eradication of polio in North America and smallpox around the world.

- - -

source: http://sanoficanada.mediaroom.com/2018-04-12-Sanofi-to-invest-EUR350-million-in-Canadian-vaccine-facility
 

Top